Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

Akcea’s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR

May 23, 2019 Sales and Marketing Akcea Therapeutics, NHS, NICE, Tegsedi, UK, pharma

Akcea Therapeutics’ Tegsedi (inotersen) has received recommendation from NICE, the company has revealed, meaning the therapy will now be made …
News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019 Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
News
spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
News
antibiotic-resistance-pill-running-from-bacteria-1500

The global rise in antibiotic resistance threatens infection prevention and cure

May 20, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
Feature
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019 Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
News
boehringer_biberach_germany_copy

Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019 Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019 Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
News
sandoz

Sandoz is first multinational to secure generic approval under new Chinese guidelines

May 20, 2019 Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin

Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
News
celgene_building

NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma

May 20, 2019 Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma

Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
News

Pfizer’s Fragmin injection secures FDA approval in paediatric symptomatic venous thromboembolism

May 17, 2019 Medical Communications, Sales and Marketing FDA, Fragmin, Pfizer, pharma

The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to …
News
lance2

A day in the life: Lance Hill, CEO at Within3

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing A day in the life, Interview, Within3, feature

Could you give a short history of how you came to be in your current role? I’ve spent my entire …
Feature

Insider Interview: Paving paths in prostate cancer

May 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
Feature

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019 Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
News
novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019 Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
News
The Gateway to Local Adoption Series

Latest content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

October 8, 2026

AstraZeneca’s Trixeo approved in EU for asthma

October 8, 2026

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

October 7, 2026

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

October 6, 2026

ESTEVE CDMO adds $17.5m to Illinois expansion

October 6, 2026